Medivation Enters into Confidentiality Agreements, Including with Sanofi
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
3 Key Takeaways as Medivation (MDVN) Enters Next Phase of Takeover Talks
July 6, 2016 7:56 AM EDTAfter the close Tuesday, Medivation (Nasdaq: MDVN) announced it entered confidentiality agreements with Sanofi (NYSE: SNY) and a number of other parties that have expressed interest acquiring the company. Before entering into the confidentiality agreement with Sanofi, Medivation rejected the latest offer from Sanofi - $58.00 per share in cash plus a Contingent Value Right for talazoparib of up to $3.00 per share. In addition to... More
